The synaptic vesicle glycoprotein 2A (SV2A) is expressed ubiquitously in neurons of the central nervous system. Due to the availability of SV2A targeting radiotracers, PET is increasingly used to study a variety of neuropsychiatric diseases. Precursor and reference compounds to synthesize [11C]UCB-J (ABX prod. no. 3420-3423) and [18F]SDM-8/[18F]SynVesT-1 (ABX prod. no. 3425-3428) are available since several years. The SynVesT-2 [1] compounds are the newest addition of SV2A radioligands to the ABX catalogue.
Learn more about this compound and send us your quote request:
ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce all compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.
Based in Radeberg, Germany, and founded in 1997, our team of about 400 employees is specialised in custom synthesis and manufacturing of precursors and peptides according to GMP for active pharmaceutical ingredients. Thanks to our expertise combined with bleeding edge equipment, we reach highest research, production, and quality standards.
ABX is the only service provider of radiopharmaceutical production with a complete and independent supply chain – from precursor or peptide to excipients and sterile disposables.
